newsmetry
rusign inget started
macro

Enveric Biosciences reports positive ADMET results for its EB-003 candidate

Biotech firm Enveric Biosciences says in vitro ADMET studies of EB-003 were favorable ahead of a planned first-in-human trial.

published on Newsmetry
original source published

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →

Newsmetry newsroom

what happened

Biotech company Enveric Biosciences has announced positive results from IND-enabling ADMET studies of its lead non-hallucinogenic neuroplastogenic candidate, EB-003, according to TradingView, which relayed the company's press release. The in vitro screen used more than 70 individual assays and showed favorable predicted intestinal absorption, low plasma protein binding and stability against liver enzymes, including those from humans.

The company also reported no significant inhibition or induction of major metabolic enzymes and transporters, which lowers the potential for drug-drug interactions. Chief Executive Joseph Tucker said the data support continued advancement toward a planned first-in-human trial.

why it matters

For markets, this is an early-stage development update from a small biotech firm. The results reduce some preclinical risk, but regulatory and financing hurdles remain, including the IND submission to the FDA and funding for clinical studies.

tags

StockUnited States

instruments

ENVB

sources

  1. Enveric Biosciences (ENVB) Reports Positive IND-Enabling ADMET Results for EB-003 — TradingView, 21 October 2026 at 12:00 UTC
  2. Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies — TradingView, 21 October 2026 at 12:00 UTC
  3. Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies — Reuters, 21 October 2026 at 12:29 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.

get stories in real time ↗

related stories